No Data
No Data
Okanvision Bio-B (01477) cancelled a total of 1.96 million repurchased shares on May 21
Okanvision Bio-B (01477) issued an announcement to cancel a total of 1 repurchased share on May 21, 2024...
What You Can Learn From Ocumension Therapeutics' (HKG:1477) P/S
When you see that almost half of the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios (or "P/S") below 1.4x, Ocumension Therapeutics (HKG:1477) looks to be giving off
歐康維視生物-B:二零二三年年報
Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug
Ocumension Therapeutics' (HKG:1477) new drug for treating postoperative inflammation successfully achieved the expected results in a phase III clinical trial, according to a Monday filing with the Hon
Okanvision Bio-B (01477.HK): Phase III clinical trial of OT-502 in China reached the main end
Gelonghui, April 15 | Okanvision Bio-B (01477.HK) announced that OT-502 (DEXYCU, dexamethasone implant), a new drug for treating post-operative inflammatory indications, has successfully reached the expected main efficacy endpoint of its phase III clinical trial. That is, on day 8, the proportion of subjects with anterior atrial atrial cell clearance (ACC grade 0) in the treatment group with dexamethasone implants was significantly higher than in the placebo group, proving that this product is safe and effective in controlling inflammation after cataract surgery. The company expects to submit an OT-502 new drug application to the Drug Evaluation Center of the China National Drug Administration in the near future. O
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
Ocumension Therapeutics (HKG:1477) said its new drug completed clinical phase III and will soon apply for a new drug registration, according to a Monday filing on the Hong Kong bourse. The drug, OT-70
No Data